A study of cabazitaxel treatment in castration resistant bone metastatic prostate cancer patients evaluating the tumor microenvironment
Phase of Trial: Phase II
Latest Information Update: 12 Oct 2017
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms CABA-BONE
- 20 Sep 2017 Planned End Date changed from 1 Feb 2018 to 1 Jul 2019.
- 20 Sep 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2018.
- 10 Jun 2017 Biomarkers information updated